Johnson & Johnson to Provide Webcast Presentation of Tapentadol Extended Release (ER) Phase 3 Clinical Data Presented at World Institute of Pain 5th Annual World Congress
NEW BRUNSWICK, N.J., March 12 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) will provide a pre-recorded webcast for financial analysts on Sunday, March 15 at 10:00 a.m. (Eastern Time) to coincide with the World Institute of Pain 5th World Congress (WIP) in New York City. Phas...
Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting
Phase 3 Safety and Efficacy Studies Will Be Highlighted
TAMPA, Fla., May 7 /PRNewswire-USNewswire/ -- Acute pain is a
significant medical issue in the United States. More than 25 million
Americans are said to experience acute pain each year as a result of
injuries or surgeries, and a recen...
New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets
RARITAN, N.J., Jan. 23 /PRNewswire-USNewswire/ -- Johnson & Johnson
Pharmaceutical Research & Development, L.L.C. announced that it has
submitted a New Drug Application (NDA) to the U.S. Food and Drug
Administration (FDA) for tapentadol
hydrochloride immediate release (IR)
tablets, an investig...
Phase II Data Show Efficacy and Tolerability of Tapentadol in Chronic Pain Treatment
The German pharmaceutical company Grunenthal GmbH presented the first clinical evidence for the efficacy and tolerability of tapentadol
ER (extended release) for patients suffering from chronic pain at the Annual Congress of the European League Against Rheumatism (EULAR), 13-16 June 2007, Barcelon...
NUCYNTA(TM) (tapentadol) CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain
....L.C. have shared development responsibilities for tapentadol
since the companies signed a licensing agreement for tapentadol
in 2003. Grunenthal licensed marketing rights to tapentadol
to Ortho-McNeil-Janssen Pharmaceuticals, Inc. for ...
A New, Highly Effective, Non-Narcotic Pain Medication Now Available for Chronic Pain Patients
...ines" Medical Director/CEO of MedsNationwide Pain Clinic-Tampa, FL.
Click here to view a video on what it takes to develop a medication like tapentadol
### Read the full story at http://www.prweb.com/...
US Back Pain Market Approaches $23 Billion in 2018 - Anticipated Long-Acting, Abuse-Resistant Opioids Drive Value
...ompete for patients and share in this market. Abuse-resistant opioids like tapentadol
CR and the antidepressant duloxetine (Cymbalta) have the greatest potential...val in Japan for the treatment of back pain, and Ortho-McNeil/ Grunenthal's tapentadol
controlled release, an opioid receptor agonist/ norepinephrine reuptake inh...
Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results
... were lower due to a decline in the market.
During the quarter, the Company announced that the U.S. Food and Drug Administration (FDA) approved tapentadol
immediate-release tablets for the relief of moderate to severe acute pain in adults 18 years of age or older. In addition, the Company submitted two ...
Scientific poster abstracts from the 24th annual meeting of the American Academy of Pain Medicine
... 6-Month Follow-up
The Pharmacokinetics of tapentadol
Are Not Affected by Omeprazole: Results of a 2-Way... Subjects
The Efficacy and Tolerability of tapentadol
Immediate Release for the Treatment of Acute Pain ... Non-Dependent, Opioid-Preferring Subjects
Extended Release (ER) for the Relief of Moderate-t...
New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
Data Confirm Tapentadol
Efficacy and Tolerability for Acute Pain Patients
RARITAN, N.J., May 26 /PRNewswire-USNewswire/ -- It is estimated that up to 30 percent of all people who have surgery experience gastrointestinal side effects, such as nausea and vomiting. The use of opioid pain medicin...
Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
Safety and Efficacy Data from Phase 3 Study will be Highlighted
SAN DIEGO, May 7 /PRNewswire-USNewswire/ -- Chronic pain is a significant medical challenge in the United States, and chronic low back pain is the most common cause of disability in developed countries. An estimated 100 million A...
FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
RARITAN, N.J., Nov. 21 /PRNewswire/ -- Millions of Americans with moderate to severe acute pain and their health-care providers will soon have a new treatment option. Today, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD), announced that the U.S. Food and Dru...
Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Osteoarthritis is a
painful and potentially debilitating condition that affects almost 50
million people in the United States. It is caused by deterioration of
cartilage in bone joints. The novel investigational pain medication
tapentadol, a central...
New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR
TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Many strong acting pain
medications have bothersome side effects. These can include nausea and
vomiting with short-term use, and constipation with longer, chronic use.
Such symptoms can lead patients to discontinue treatment, adding additional
New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery
Novel Pain Medicine Studied in Patients Following Bunionectomy
TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Many foot-surgery
patients experience intense pain for several days following removal of a
bunion, one of the most common foot surgeries. The investigational pain
Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Society's Annual Meeting
NEW BRUNSWICK, N.J., May 7 /PRNewswire-FirstCall/ -- Johnson & Johnson
will provide a pre-recorded webcast for financial analysts on Friday, May 9
at 4:00 p.m. (Eastern Time) to coincide with the American Pain Society's
(APS) annual meeting in Tampa, Fla. Phase 3 clinical data presentations on...